<DOC>
	<DOCNO>NCT02956005</DOCNO>
	<brief_summary>The purpose study collect data prospectively African American patient take immunosuppressant Envarsus post kidney transplant . We look see African American renal transplant recipient receive Envarsus less tubular injury calcenurin inhibitor toxicity compare patient receive tacrolimus IR . African american high rate CYP3A5 associate need high tacrolimus dose achieve adequate level many time associated sign symptom tacrolimus toxicity tremor , headache neuropathy . The retrospective cohort African American patient match age , gender , type kidney transplant ( live v decease ) level sensitization</brief_summary>
	<brief_title>Envarsus XR African American Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . African American race 2 . Adult renal transplant recipient ( &gt; 18 y/o ) 3 . Previous adverse reaction contraindication use tacrolimus 1 . Non African American race 2 . Less 18 y/o ( pediatric patient ) 3 . Recipients liver small bowel transplant 4 . Adverse reaction tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>